A roadmap to precision treatments for familial pulmonary fibrosis - Maladies génétiques d'expression pédiatrique Accéder directement au contenu
Article Dans Une Revue EBioMedicine Année : 2024

A roadmap to precision treatments for familial pulmonary fibrosis

Résumé

Interstitial lung diseases (ILDs) in adults and children (chILD) are a heterogeneous group of lung disorders leading to inflammation, abnormal tissue repair and scarring of the lung parenchyma often resulting in respiratory failure and death. Inherited factors directly cause, or contribute significantly to the risk of developing ILD, so called familial pulmonary fibrosis (FPF), and monogenic forms may have a poor prognosis and respond poorly to current treatments. Specific, variant-targeted or precision treatments are lacking. Clinical trials of repurposed drugs, anti-fibrotic medications and specific treatments are emerging but for many patients no interventions exist. We convened an expert working group to develop an overarching framework to address the existing research gaps in basic, translational, and clinical research and identified areas for future development of preclinical models, candidate medications and innovative clinical trials. In this Position Paper, we summarise working group discussions, recommendations, and unresolved questions concerning precision treatments for FPF.
Fichier principal
Vignette du fichier
PIIS2352396424001701.pdf (1.16 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04592375 , version 1 (29-05-2024)

Licence

Identifiants

Citer

Killian Hurley, Mari Ozaki, Quentin Philippot, Liam Galvin, David Crosby, et al.. A roadmap to precision treatments for familial pulmonary fibrosis. EBioMedicine, 2024, 104, pp.105135. ⟨10.1016/j.ebiom.2024.105135⟩. ⟨hal-04592375⟩
4 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More